BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 14648019)

  • 1. Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
    Berger U; Engelich G; Reiter A; Hochhaus A; Hehlmann R;
    Ann Hematol; 2004 Apr; 83(4):258-64. PubMed ID: 14648019
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG; Guilhot F; Larson RA; Gathmann I; Baccarani M; Cervantes F; Cornelissen JJ; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Rousselot P; Reiffers J; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Kantarjian H; Taylor K; Verhoef G; Bolton AE; Capdeville R; Druker BJ;
    N Engl J Med; 2003 Mar; 348(11):994-1004. PubMed ID: 12637609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
    Hahn EA; Glendenning GA; Sorensen MV; Hudgens SA; Druker BJ; Guilhot F; Larson RA; O'Brien SG; Dobrez DG; Hensley ML; Cella D;
    J Clin Oncol; 2003 Jun; 21(11):2138-46. PubMed ID: 12775739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Anstrom KJ; Reed SD; Allen AS; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2584-92. PubMed ID: 15493041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG; Deininger MW
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):26-30. PubMed ID: 12783372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
    Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
    Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Imatinib combination therapies--the new CML Study 4].
    Helmann R; Berger U; Engelich G
    Dtsch Med Wochenschr; 2002 Oct; 127(42):224-6. PubMed ID: 12430568
    [No Abstract]   [Full Text] [Related]  

  • 10. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
    Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
    Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
    Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
    N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
    Cortes J; O'Brien S; Quintas A; Giles F; Shan J; Rios MB; Talpaz M; Kantarjian H
    Cancer; 2004 Jun; 100(11):2396-402. PubMed ID: 15160343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
    Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Faderl S; Wierda W; Rios MB; Shan J; Cortes J
    Cancer; 2005 Aug; 104(4):777-80. PubMed ID: 15971197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
    Carella AM
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
    [No Abstract]   [Full Text] [Related]  

  • 17. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
    Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
    Haematologica; 2010 Aug; 95(8):1415-9. PubMed ID: 20305139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia.
    Ezaki K
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():279-84. PubMed ID: 10895166
    [No Abstract]   [Full Text] [Related]  

  • 19. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
    Palandri F; Iacobucci I; Castagnetti F; Testoni N; Poerio A; Amabile M; Breccia M; Intermesoli T; Iuliano F; Rege-Cambrin G; Tiribelli M; Miglino M; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M;
    Haematologica; 2008 May; 93(5):770-4. PubMed ID: 18367490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
    Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.